|
1
|
Kidney cancer update the year in review in
kidney cancer. Clin Adv Hematol Oncol. 13:327–329. 2015.PubMed/NCBI
|
|
2
|
Massari F, Di Nunno V, Ciccarese C, Graham
J, Porta C, Comito F, Cubelli M, Iacovelli R and Heng DYC: Adjuvant
therapy in renal cell carcinoma. Cancer Treat Rev. 60:152–157.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Posadas EM, Limvorasak S and Figlin RA:
Targeted therapies for renal cell carcinoma. Nat Rev Nephrol.
13:496–511. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cha TL, Chuang MJ, Wu ST, Sun GH, Chang
SY, Yu DS, Huang SM, Huan SK, Cheng TC, Chen TT, et al: Dual
degradation of aurora A and B kinases by the histone deacetylase
inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer
cells. Clin Cancer Res. 15:840–850. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kurahashi T, Miyake H, Hara I and Fujisawa
M: Significance of Aurora-A expression in renal cell carcinoma.
Urol Oncol. 25:128–133. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li Y, Zhou W, Wei L, Jin J, Tang K, Li C,
Teh BT and Chen X: The effect of Aurora kinases on cell
proliferation, cell cycle regulation and metastasis in renal cell
carcinoma. Int J Oncol. 41:2139–2149. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Karthigeyan D, Prasad SB, Shandilya J,
Agrawal S and Kundu TK: Biology of Aurora A kinase: Implications in
cancer manifestation and therapy. Med Res Rev. 31:757–793.
2011.PubMed/NCBI
|
|
8
|
Borisa AC and Bhatt HG: A comprehensive
review on Aurora kinase: Small molecule inhibitors and clinical
trial studies. Eur J Med Chem. 140:1–19. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lim SK and Gopalan G: Aurora-A kinase
interacting protein 1 (AURKAIP1) promotes Aurora-A degradation
through an alternative ubiquitin-independent pathway. Biochem J.
403:119–127. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Eckerdt F, Pascreau G, Phistry M, Lewellyn
AL, DePaoli-Roach AA and Maller JL: Phosphorylation of TPX2 by Plx1
enhances activation of Aurora A. Cell Cycle. 8:2413–2419. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang Y, Li T, Ems-McClung SC, Walczak CE,
Prigent C, Zhu X, Zhang X and Zheng Y: Aurora A activation in
mitosis promoted by BuGZ. J Cell Biol. 217:107–116. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Korobeynikov V, Deneka AY and Golemis EA:
Mechanisms for nonmitotic activation of Aurora-A at cilia. Biochem
Soc Trans. 45:37–49. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Compérat E, Bièche I, Dargère D,
Laurendeau I, Vieillefond A, Benoit G, Vidaud M, Camparo P, Capron
F, Verret C, et al: Gene expression study of Aurora-A reveals
implication during bladder carcinogenesis and increasing values in
invasive urothelial cancer. Urology. 72:873–877. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Goktas S, Yildirim M, Suren D, Alikanoglu
AS, Dilli UD, Bulbuller N, Sezer C and Yildiz M: Prognostic role of
Aurora-A expression in metastatic colorectal cancer patients. J
BUON. 19:686–691. 2014.PubMed/NCBI
|
|
15
|
Twu NF, Yuan CC, Yen MS, Lai CR, Chao KC,
Wang PH, Wu HH and Chen YJ: Expression of Aurora kinase A and B in
normal and malignant cervical tissue: High Aurora A kinase
expression in squamous cervical cancer. Eur J Obstet Gynecol Reprod
Biol. 142:57–63. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu J, Li H, Wang B, Xu Y, Yang J, Zhang X,
Harten SK, Shukla D, Maxwell PH, Pei D and Esteban MA: VHL
inactivation induces HEF1 and Aurora kinase A. J Am Soc Nephrol.
21:2041–2046. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hasanov E, Chen G, Chowdhury P, Weldon J,
Ding Z, Jonasch E, Sen S, Walker CL and Dere R: Ubiquitination and
regulation of AURKA identifies a hypoxia-independent E3 ligase
activity of VHL. Oncogene. 36:3450–3463. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gossage L, Eisen T and Maher ER: VHL, the
story of a tumour suppressor gene. Nat Rev Cancer. 15:55–64. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim BJ, Kim JH, Kim HS and Zang DY:
Prognostic and predictive value of VHL gene alteration in renal
cell carcinoma: A meta-analysis and review. Oncotarget.
8:13979–13985. 2017.PubMed/NCBI
|
|
20
|
Ferchichi I, Kourda N, Sassi S, Romdhane
KB, Balatgi S, Cremet JY, Prigent C and Elgaaied AB: Aurora A
overexpression and pVHL reduced expression are correlated with a
bad kidney cancer prognosis. Dis Markers. 33:333–340. 2012.
View Article : Google Scholar : PubMed/NCBI
|
